StockData
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30

AYTU BIOPHARMA, INC

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026
$1.96−0.08 (-3.92%)

Close on Oct 19, 2026

Market cap
$37.82M
P/E (TTM)
–
Dividend yield
–

AYTU BIOPHARMA, INC revenue by segment

By business segment

RevenueQ4 26Q3 26Q2 26Q1 26Q4 25Q3 25Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24% of revenueYoY
RX Segment [Member]$16.11M$12.41M$15.17M–$15.14M$18.45M$16.22M–––––100.0%+6.4%
Consumer Health [Member]––––––––$3.38M$3.97M$4.19M$4.28M––
Rx–––––––––––$17.82M––
Rx Segment [Member]–––$13.89M$15.14M$18.45M$16.22M$16.57M$14.59M$14.03M$18.75M$17.82M––
Operating incomeQ4 26Q3 26Q2 26Q1 26Q4 25Q3 25Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24YoY
Consumer Health [Member]––––––––-$1.38M-$866.00K-$782.00K-$638.00K–
Rx–––––––––––-$866.00K–
Rx Segment [Member]––––––––-$2.27M-$1.60M$3.15M––

By product or service

RevenueQ4 26Q3 26Q2 26Q1 26Q4 25Q3 25Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24% of revenueYoY
Pediatric–––––––––––$2.57M––
ADHD–––––––––––$15.13M––
Other–––––––––––$124.00K––

By region

From the segment and revenue-disaggregation notes of Aytu Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.